Zepbound and Mounjaro Dose Escalation Schedule: The Official Tirzepatide Titration Guide
The tirzepatide escalation schedule
Tirzepatide (Zepbound/Mounjaro) escalates in 5 stages from a 2.5 mg starter dose to the maximum 15 mg dose over 20 weeks. The schedule is identical for both the Zepbound (obesity) and Mounjaro (T2D) formulations.
| Stage | Dose | Duration | Target for most patients |
|---|---|---|---|
| 1 | 2.5 mg weekly | Weeks 1–4 | Starter dose only (not therapeutic) |
| 2 | 5 mg weekly | Weeks 5–8 | First therapeutic dose |
| 3 | 7.5 mg weekly | Weeks 9–12 | Standard efficacy |
| 4 | 10 mg weekly | Weeks 13–16 | High efficacy |
| 5 | 12.5 mg weekly | Weeks 17–20 | Near-maximum efficacy |
| 6 | 15 mg weekly | Week 21 onwards | Maximum dose |
Note: The 15 mg maximum applies to Zepbound (obesity). Mounjaro for T2D uses the same escalation but with a maximum of 15 mg/week as well.
How the Zepbound escalation compares to Wegovy
| Tirzepatide (Zepbound) | Semaglutide (Wegovy) | |
|---|---|---|
| Starter dose | 2.5 mg | 0.25 mg |
| Final dose | 15 mg | 2.4 mg |
| Steps to maintenance | 6 | 5 |
| Weeks to full maintenance | 20–24 | 16–20 |
| Maximum dose | 15 mg/week | 2.4 mg/week |
Note: These are different molecules measured in the same unit (mg) — the doses are not clinically comparable as a number. For a full efficacy comparison, see tirzepatide vs semaglutide.
What to expect at each dose stage
2.5 mg (weeks 1–4)
The sub-therapeutic starter dose. Most patients experience minimal appetite change and few GI symptoms. Some patients notice mild nausea 24–48 hours after injection, which typically resolves quickly. This stage exists entirely for tolerability initiation. For a week-by-week account of what to expect, see GLP-1 week-by-week results.
5 mg (weeks 5–8)
The first therapeutically meaningful dose. Appetite suppression typically begins here. Nausea is most common at this transition for most patients — the 2–3 days after the first 5 mg injection tend to be the worst. The body adapts within 2 weeks for most patients.
7.5 mg (weeks 9–12)
Significant therapeutic effects. Meaningful weight loss typically accelerating. GI symptoms usually more manageable than at 5 mg for most patients as adaptation has occurred.
10 mg (weeks 13–16)
High-efficacy range. The SURMOUNT trial showed the 10 mg dose achieving approximately 19.5% weight loss at 72 weeks — close to the maximum dose effect.
12.5 mg (weeks 17–20)
Near-maximum efficacy. Some patients plateau here rather than continuing to 15 mg.
15 mg (week 21 onwards)
The maximum approved dose. SURMOUNT-1 showed approximately 20.9% average weight loss at 72 weeks at this dose. Side effects are typically no worse than at 12.5 mg for most patients who have tolerated the escalation.
Maintenance doses: not everyone needs 15 mg
The SURMOUNT trial included arms for 5 mg, 10 mg, and 15 mg. Outcomes differed:
| Dose | Average weight loss at 72 weeks |
|---|---|
| 5 mg | ~15% |
| 10 mg | ~19.5% |
| 15 mg | ~20.9% |
The 5 mg and 10 mg doses produce substantial weight loss. Patients who achieve their therapeutic goals at 10 mg and tolerate it well have clinical reason to remain at 10 mg rather than continuing to 15 mg — particularly if GI side effects worsen at higher doses.
Who may stabilise below 15 mg:
- Patients who have achieved their weight loss goal at 10 mg or 12.5 mg
- Patients with significant GI side effects at higher doses
- Patients managing cost (higher doses have the same list price but some programmes limit to specific doses)
Managing the escalation: practical guidance
Side effects peak at each transition. The worst GI symptoms occur in the 24–72 hours after each dose increase. This is expected and does not mean the drug is not working or that the dose is too high. It typically settles within 1–2 weeks of the new dose.
Extended time at a dose is allowed. The prescribing label allows for 4 additional weeks at any step if side effects are unacceptable:
"If toleration of tirzepatide is an issue, the dose escalation may be delayed by 4 weeks."
Patients experiencing significant nausea, vomiting, or GI symptoms at a given dose can and should request extended time at that dose before advancing.
Injection day management: Most patients find side effects are least severe when injected on a day when they can eat a small meal beforehand and avoid intense physical activity for 24 hours. Evening injection (so any nausea occurs overnight) is a common preference.
What happens if you need to pause or restart
Short pause (less than 2 weeks): Resume at your usual dose.
Pause of 2–4 weeks: Most prescribers recommend dropping one dose step and re-escalating over 4 weeks.
Pause of more than 4 weeks: Follow prescriber guidance — may involve restarting from the beginning of the escalation or from a specific dose depending on how much the pause was.
The 2.5 mg "maintenance" off-label discussion
Some prescribers and patients explore very-low-dose tirzepatide (2.5 mg) as a long-term maintenance dose after reaching goal weight, reasoning that a small amount of ongoing GLP-1/GIP stimulation can maintain metabolic benefits without full weight loss dosing. This is off-label and not supported by SURMOUNT data, which showed the 5 mg dose as the minimum studied. The evidence for sub-5 mg maintenance is limited.
Compounded tirzepatide: similar schedule, variable formulations
Compounded tirzepatide is available through §503A pharmacies at significantly lower cost than branded Zepbound. The dose escalation schedule is similar to the branded version, but:
- Concentrations vary by compounding pharmacy
- Volume-per-dose calculations differ from pen-based administration
- Some providers use slightly different escalation increments
Always follow the dosing instructions from your specific compounding pharmacy and confirm the dose calculation with your prescriber. For eligibility requirements before starting tirzepatide, see GLP-1 eligibility criteria.
Summary
Tirzepatide's dose escalation runs from 2.5 mg to 15 mg over 20–24 weeks in 2.5 mg increments every 4 weeks. The starter dose (2.5 mg) is sub-therapeutic; therapeutic effects begin at 5 mg. GI side effects peak at each transition and typically resolve within 1–2 weeks. Extended time at any dose step is explicitly allowed in the label. Many patients stabilise at 10 mg rather than needing the full 15 mg dose.